Overcoming Clinical Inertia In Diabetes
CARDIOMETABOLIC CASE STUDIES IN DIABETES 2017

Saturday, November 18, 2017
9:00 am - 3:20 pm
Delta Hotel Toronto Airport & Conference Centre,
655 Dixon Road,
Toronto, ON M9W 1J3

Program Chair:
Ronald M. Goldenberg,
MD, FRCP, FACE
Consultant Endocrinologist,
North York General Hospital &
LMC Diabetes & Endocrinology,
Thornhill, ON

Keynote Speaker:
John B. Buse,
MD, PhD
Verne S. Cavinness
Distinguished Professor
Chief, Division of Endocrinology
Director, Diabetes Center
Director, NC Translational and Clinical
Sciences Institute
University of North Carolina
School of Medicine

Faculty:

Alice Y. Y. Cheng,
MD, FRCP
Division of Endocrinology & Metabolism,
Credit Valley Hospital and
St. Michael's Hospital
Associate Professor of Medicine,
University of Toronto

Philip A. McFarlane,
MD, PhD, FRCP
Medical Director, Home Dialysis
Division of Nephrology,
St. Michael's Hospital
Assistant Professor of Medicine,
University of Toronto

Subodh Verma,
MD, PhD, FRCSC, FAHA
Cardiac Surgeon,
St. Michael’s Hospital,
Scientist, Keenan Research Centre
for Biomedical Science and Li Ka
Shing Knowledge Institute of
St. Michael’s Hospital,
Professor of Surgery and
Pharmacology & Toxicology,
University of Toronto
Toronto, ON

Agenda

8:00 am Registration and Breakfast
9:00 am Opening Remarks
Ronald M. Goldenberg

9:10 am Keynote Lecture
Incretins: From Bench to Bedside
John B. Buse

9:55 am Health break

10:10 am Clinical Inertia and Cardio-renal-metabolic Issues in T2D
10:10 am Clinical Inertia in T2D: The Role of Early or Initial Combination Therapy
Alice Y.Y. Cheng

10:30 am Cardiovascular Safety and Efficacy - What’s the Best Combination?
Subodh Verma

10:50 am Renal Safety and Efficacy - What’s the Best Combination?
Philip A. McFarlane

11:10 am Safety Issues with Incretin Agents and SGLT2 Inhibitors: What You Need to Know
Ronald M. Goldenberg

11:30 am Q&A / Panel Discussion

12:00 pm Lunch

1:00 pm Case Studies in Type 2 Diabetes
1:00 pm A Case for Earlier Intervention with Combination Therapy
Alice Y.Y. Cheng

1:20 pm DPP-4 Inhibitor or SGLT2 Inhibitor: How to Choose?
Ronald M. Goldenberg

1:40 pm A Case to Illustrate the Relevance of DPP-4 Inhibitors in Individuals with Type 2 Diabetes and Cardiovascular Disease
Subodh Verma

2:00 pm A Case Where Renal Function is Sub-optimal
Philip A. McFarlane

2:20 pm Individualizing Therapy
Primary vs Secondary Prevention and DPP-4 Inhibitors vs SGLT2 Inhibitors vs GLP-1 Receptor Agonists
Ronald M. Goldenberg, Subodh Verma and Alice Y.Y. Cheng

2:50 pm Q&A / Panel Discussion

3:20 pm Closing Remarks
Ronald M. Goldenberg